Timapiprant
As of the edition of 20 October 2026, Timapiprant is a small molecule: went quiet in 2018; acts on PTGDR2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2018
- Kind
- Small molecule
- Registered trials
- 9, 0 stopped early
- Disease areas
- Immune system; Lungs and airways; Blood and lymph; Ear, nose and throat; Digestive system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Timapiprant.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGDR2 | Prostaglandin D2 receptor 2 | Q9Y5Y4 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 7 | 7 | 0 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Oxagen | Lead sponsor of trials | 2007 to now |
| Atopix Therapeutics | Lead sponsor of trials | 2013 to now |